Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

NCT00860158 is registered in ClinicalTrials.gov with Noah Hahn, M.D. as lead sponsor.

NCT NCT00860158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00860158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Lead sponsor
Noah Hahn, M.D.
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2009
Completion date
December 31, 2010
Enrollment
1 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer